We have updated our Terms of Use.
Please read our new Privacy Statement before continuing.

Patient cliff

27 April 2017 By Neil Unmack

The drugmaker’s revenue fell 10 percent in the first quarter, despite a boost from non-recurring sales. Losing patents has hurt Astra’s pricing power. Winning approval for new drugs would help boss Pascal Soriot rebuild. Investors are not fully factoring in that possibility.

This content is for Subscribers only


Email a friend

Please complete the form below.

Required fields *


(Separate multiple email addresses with commas)